Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma
- 8 August 2013
- Vol. 154 (6) , 1199-1205
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- No Evidence for BRAF-V600E Mutations in Gastroeosophageal TumorsApplied Immunohistochemistry & Molecular Morphology, 2013
- Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibodyActa Neuropathologica, 2011
- Factors influencing the detection of the BRAF T1799A mutation in papillary thyroid carcinomaOncology Reports, 2011
- Higher rate of BRAF mutation in papillary thyroid cancer over timeCancer, 2011
- The Utility of BRAF Testing in the Management of Papillary Thyroid CancerThe Oncologist, 2010
- Spry2 expression correlates with BRAF mutation in thyroid cancerSurgery, 2010
- Detection ofBRAFMutations in Thyroid Nodules by Allele-Specific PCR Using a Dual Priming Oligonucleotide SystemAmerican Journal of Clinical Pathology, 2010
- Pyrosequencing Analysis for Detection of a BRAFV600E Mutation in an FNAB Specimen of Thyroid NodulesDiagnostic Molecular Pathology, 2008
- Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosisExpert Review of Molecular Diagnostics, 2008
- Increasing Incidence of Thyroid Cancer in the United States, 1973-2002JAMA, 2006